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Background: Hyperosmolar agents frequently are used to decrease intracranial pres-
sure but their effects on electrolyte and acid-base variables have not been prospec-
tively investigated.
Objectives: Compare duration and magnitude of changes in electrolyte and acid-base
variables after hyperosmolar treatment.
Animals: Twenty-eight client-owned dogs with intracranial hypertension caused by
various pathologies.
Methods: Prospective, randomized, nonblinded, experimental cohort study. Fifteen
dogs received a single dose (4 mL/kg) of 7.2% hypertonic saline (HTS), 13 dogs
received 20% mannitol (MAN) 1 g/kg IV. Electrolyte and acid-base variables were
measured before (T0), and 5 (T5), 60 (T60), and 120 (T120) minutes after administra-
tion. Variables were compared between treatments and among time points within
treatment groups.
Results: Mean plasma sodium and chloride concentrations were higher after HTS
than MAN at T5 (158 vs 141 mEq/L; 126 vs 109 mEq/L) and significant differences
were maintained at all time points. After HTS, plasma sodium and chloride concentra-
tions remained increased from T0 at all time points. After MAN, plasma sodium and
chloride concentrations decreased at T5, but these changes were not maintained at
T60 and T120. Plasma potassium concentration was lower at T5 after HTS compared
with T0 (3.6 vs 3.9 mEq/L) and compared to MAN (3.6 vs 4.1 mEq/L). At T60 and
T120, plasma ionized calcium concentration was lower after HTS than MAN (1.2 vs
1.3 mmol/L). No significant differences were found in acid-base variables between
treatments.
Conclusions and Clinical Importance: At the administered dose, dogs receiving HTS
showed sustained increases in plasma sodium and chloride concentrations, whereas
dogs receiving MAN showed transient decreases. Future studies should assess the
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effects of multiple doses of hyperosmolar agents on electrolyte and acid-base
variables.
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1 | INTRODUCTION
Intracranial hypertension (ICH) is a potentially life-threatening neuro-
logical emergency that can develop secondary to a variety of acute
and chronic intracranial disease processes, such as traumatic brain
injury (TBI), intracranial neoplasia, meningoencephalitis, hemorrhage,
and status epilepticus.1-4 Treatment for acute ICH is multimodal and
influenced by the underlying cause, but a mainstay of medical treat-
ment in both humans and small animals is the early administration of
hyperosmolar agents.4-8 The goal of IV hyperosmolar agents is
osmotic mobilization of intracellular and interstitial water from non-
traumatized brain tissue into the intravascular space. An intact blood-
brain barrier is a prerequisite for the efficacy of hyperosmolar treat-
ment. If this condition is met, osmotic shifts decrease intracranial vol-
ume and intracranial pressure, and cerebral perfusion pressure
improves.4,9
Mannitol (MAN) and hypertonic saline (HTS) are the most exten-
sively studied hyperosmolar agents for the treatment of ICH, and
MAN remains the gold standard for the treatment of ICH in TBI
patients.5,6,10 More recently, HTS solutions of variable concentrations
have been advocated as an alternative to MAN. It has been suggested
that HTS might be superior in the treatment of ICH and in improving
cerebral perfusion in humans and dogs.11-15 Furthermore, HTS does
not cause the pronounced and sustained diuresis that can be seen
after MAN administration and therefore is less likely to put patients at
risk of dehydration and hypovolemia.16-18
Both HTS and MAN administration have been implicated in the
pathogenesis of clinically relevant alterations in electrolyte and acid-
base balance in people and dogs. Plasma sodium concentrations are
expected to increase after HTS administration, whereas MAN admin-
istration can cause dilutional hyponatremia because of water shifts
into the intravascular space.19 In people, potentially life-threatening
hyperkalemia can occur after hyperosmolar IV volume expansion.20-23
The most noticeable change in acid-base balance after administration
of HTS is hyperchloremic metabolic acidosis, as a result of a more
marked increase in plasma chloride concentration as compared with
sodium concentration.24-26 In contrast, by the induction of diuresis,
MAN is more likely to favor development and maintenance of meta-
bolic alkalosis.18,27,28 Extensive literature on HTS and MAN treatment
exists, but prospective, randomized comparisons of the electrolyte
and acid-base effects of these 2 agents in dogs suffering from natu-
rally occurring ICH caused by various underlying pathologies are
lacking.
Our objective was to compare the duration and magnitude of
effects on commonly measured electrolyte concentrations and acid-
base variables of IV administered 7.2% HTS and 20% MAN in client-
owned dogs with evidence of ICH, measured at 5 (T5), 60 (T60), and
120 (T120) minutes after administration.
2 | MATERIALS AND METHODS
Data collection for our study occurred simultaneously with data col-
lection for a study investigating the effects of 7.2% HTS and 20%
MAN in dogs with ICH on osmolarity, whole blood coagulation, and
platelet function previously conducted at our institution.29
The study was designed as a prospective, randomized, nonblinded
experimental trial. Client-owned dogs presented to the Veterinary
Medical Teaching Hospital at the University of Bern, Switzerland with
evidence of ICH were prospectively screened for study enrollment
between March 2013 and March 2016.
A diagnosis of ICH was made based on patient history, compati-
ble clinical signs on neurologic examination, and supportive findings
on magnetic resonance (MRI) or computed tomographic (CT) imaging
studies, if available. Patient histories that included head trauma or
polytrauma, preexisting intracranial neurologic signs raising a suspi-
cion for or previously diagnosed intracranial neoplasia, inflammatory
or infectious encephalopathies, ingestion of toxic substances with the
potential for central nervous system manifestations, or prolonged
status epilepticus in conjunction with compatible clinical signs were
considered supportive of ICH. Neurologic examination by a board-
certified neurologist was performed on every patient. Patients admit-
ted by the Neurology Service had a neurologic examination conducted
immediately, whereas consultation by a board-certified neurologist
was performed within the first hour of patient admission for patients
of the Emergency and Critical Care Service. Clinical criteria to sub-
stantiate the suspicion of ICH included a neuroanatomical localization
to the forebrain or multifocal disease, severely altered mentation and
miotic pupils, presence of a documented Cushing reflex (bradycardia
and concurrent systemic hypertension), lack of improvement after
cardiovascular stabilization, or deterioration of a patient's modified
Glasgow Coma Scale score.30 Evidence of intracranial mass effects, peri-
lesional edema, transtentorial brain herniation, or other shifts of brain
parenchyma on CT or MRI studies were considered indicative of ICH.31
The decision to administer hyperosmolar treatment to any patient
with the aforementioned criteria was at the primary clinician's discre-
tion. Patients were included in the study if they had evidence of ICH
warranting hyperosmolar treatment. Exclusion criteria from study par-
ticipation included azotemia (plasma creatinine concentration
>1.58 mg/dL), body weight <7 kg, age <6 months or >12 years,
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presence of diseases known to affect whole blood coagulation or
platelet function, anemia, thrombocytopenia, and previous administra-
tion of hyperosmolar agents, synthetic colloids, or blood products
within 2 weeks of study enrollment. Patients that were euthanized
during the study period because of the severity of disease were not
excluded from the study.
If hyperosmolar treatment was deemed indicated, dogs were ran-
domized to receive either 7.2% HTS (Dr G. Bichsel AG, Interlaken, Swit-
zerland) or 20% MAN (Dr G. Bichsel AG, Interlaken, Switzerland) by
drawing a sealed study envelope containing a numbered card. A single
bolus of the assigned study drug was administered as 7.2% HTS 4 mL/kg
IV over 5 minutes or 20% MAN 1 g/kg (5 mL/kg) IV over 15 minutes
using a syringe pump. Animals were excluded from the study if additional
hyperosmolar treatments were administered during the study period.
Additional isotonic crystalloid fluid therapy during the study period was
allowed and administered at the primary clinician's discretion.
The Animal Experiment Committee of the Swiss Federal Veteri-
nary Office approved the trial (registration number BE 90/13) and
written informed owner consent was obtained for enrolled dogs. Clini-
cal data collected on study participants included signalment (breed,
age, and sex), body weight, the diagnosed or suspected underlying dis-
ease causing ICH, and the type and amount of additional isotonic
crystalloid fluids administered throughout the study period.
Blood samples for assessment of electrolyte and acid-base variables
were obtained before (T0) administration of the hyperosmolar treatment
and 5 (T5), 60 (T60), and 120 (T120) minutes thereafter by direct venipunc-
ture of the lateral saphenous vein. All blood samples were obtained using
a 21G butterfly needle and vacutainer system and were collected by the
same investigator (author I.D. Yozova). Blood samples for this study and
the study evaluating the effects of hyperosmolar treatments on whole
blood coagulation and platelet function29 were collected in the following
order: discard tube, 2 3.2% buffered sodium citrate tubes (BD vacutainer
1.8 mL coagulation tube, buffered trisodium citrate 3.2%, BD, Plymouth,
United Kingdom) for coagulation assessments, 1 heparin tube (Li-Heparin
LH 1.3, 1.3 mL tubes, Sarsteds AG, Sevelen, Switzerland) for assessment
of plasma electrolyte concentrations and acid-base variables, and 1 K2-
EDTA tube (K2EDTA 2 mL tubes, Sarstedt AG) for hematological ana-
lyses. Full plasma biochemical profiles were not performed as part of this
study and their request was at the discretion of the primary clinician.
Electrolyte and acid-base analyses were performed within 5 minutes
of sample collection using a commercial blood gas analyzer (RAPIDPoint
500; Siemens Healthcare AG). Analytes measured by the analyzer
included pH, venous partial pressure of carbon dioxide (PvCO2), and
plasma concentrations of sodium, chloride, potassium, and ionized cal-
cium. Corrected chloride concentration was calculated based on the fol-
lowing formula: [Chloridecorrected] = [Chloridemeasured] × ([Sodiumnormal]/
[Sodiummeasured])
32 and 147 mEq/L was used as the mid-range normal
plasma sodium concentration based on previously established institutional
reference intervals (RI).33 Actual bicarbonate and standardized bicarbon-
ate concentrations, anion gap (AG), and extracellular and blood base
excess (BE) were calculated by the analyzer. The AG corrected for albu-
min concentration (AGcorr) was calculated based on the following formula:
AGcorr = AG + 4.2 × (3.77 − plasma albumin concentration in g/dL).34
Strong ion difference (SID) was calculated based on the fol-
lowing formula: SID = ([sodium] + [potassium] + [ionized calcium])
− [chloride] in mmol/L.35 Institutional RI for the RAPIDPoint
500 blood gas analyzer had been established previously using
healthy dogs.33
2.1 | Statistical Analysis
A sample size calculation was performed to allow the detection of
meaningful differences in acid-base status and the primary end-
point was pH. It rendered at least 9 vs 7 patients required in each
treatment group to detect differences in pH from 7.35 to 7.45 and
standard deviation (SD) of 0.07 for significance levels of 0.05 and
0.01, respectively, and 80% power (Software PASS, https://www.
ncss.com/software/pass/). Secondary endpoints included plasma
electrolyte concentrations and respiratory and metabolic acid-base
variables.
Statistical analyses were performed using commercially avail-
able software (Prism 8.0, Graph Pad Software, La Jolla, California).
Normality testing was performed on continuous variables using the
Shapiro-Wilk test and by visually examining histogram plots. Data
are presented as mean ± SD for normally distributed data and
median (range) or median (interquartile range) for nonnormally dis-
tributed data. Population characteristics between the 2 patient
groups receiving HTS and MAN were evaluated using Student's
t test or Mann-Whitney U test for normally and non-normally dis-
tributed continuous data, respectively. Fisher's exact test was used
for categorical data.
Comparison of electrolyte and acid-base variables among patients
receiving HTS and those receiving MAN at each sampling time point
was performed using Student's t test or Mann-Whitney U test. Within
each treatment group, changes in electrolyte and acid-base variables
with respect to a previous time point were assessed using repeated
measures analysis of variance, Friedman test, or residual maximum
likelihood ratio mixed effects models, for complete normally distrib-
uted, complete nonnormally distributed, and incomplete sets of paired
data, respectively. Post hoc analyses were performed using Tukey's or
Dunn's multiple comparisons tests. Bonferroni corrections were
applied to adjust for multiple comparisons where appropriate. To
avoid discarding weak but relevant effects, and because of the pres-
ence of missing values for some variables, use of a strict level of sig-
nificance was avoided and P values interpreted as the gradient from
0 to 1.
3 | RESULTS
3.1 | Study population
Twenty-eight dogs with suspected ICH were prospectively included in
the study, 15 in the HTS group and 13 in the MAN group. Available mea-
surements from the 28 dogs at the individual sampling time points are
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presented in Tables 1 and 2. Represented breeds included French bulldog
(n = 4), Golden Retriever (n = 4), mixed-breed (n = 4), Labrador Retriever
(n = 2), Border Collie (n = 2), and 1 each of Flat Coated Retriever, Cocker
Spaniel, Boxer, Fox Terrier, German Shepherd Dog, Great Dane, Jack
Russell-Terrier, Keeshond, Malinois, Saint Bernard, Tervuren, and
Mudi. Sixteen dogs were male (9 intact, 7 neutered) and 12 were
female (4 intact, 8 spayed). Dogs had a median age of 6 years and
3 months (range, 1 year and 1 month to 12 years and 6 months) and
median body weight of 24.3 kg (range, 7.2-52.8 kg). No significant
differences in signalment or body weight were found between the
2 treatment groups (age, P = .87; sex, P = .45; body weight, P = .40).
Diagnostic imaging was available for 22 dogs and consisted of an
MRI study in 21 and CT study in 2 dogs. One dog had both an MRI
and CT of the head performed. Underlying diseases suspected to
cause ICH included intracranial neoplasia (HTS group, n = 8; MAN
group, n = 7), intoxication (HTS group, n = 1; MAN group, n = 2),
head trauma (HTS group, n = 1; MAN group, n = 2), meningoenceph-
alitis (MAN group, n = 2), hydrocephalus (HTS group, n = 1),
presumptive hypertensive encephalopathy (HTS group, n = 1), and
undetermined in 3 dogs in the HTS group.
In some patient samples, not all planned measurements could be
carried out because of technical difficulties (blood clotting or machine
electrode errors). In addition, blood samples from 5 dogs at T60 and
another 3 dogs at T120 could not be obtained because of euthanasia
before the measurement time points.
3.2 | Additional IV isotonic crystalloid fluid therapy
Twenty-three dogs (HTS group, n = 12, MAN group, n = 11) received
balanced isotonic crystalloid fluids IV during the study period. Three
dogs in the HTS and 2 in the MAN group received lactated Ringer's
solution (Fresenius Kabi [Schweiz] AG, Kriens, Switzerland) solution and
the remaining dogs (HTS n = 9, MAN n = 9) received Plasma-Lyte A
(Baxter AG, Opfikon, Switzerland). The mean administered isotonic crys-
talloid fluid amount in ml/kg over the study period was not significantly
TABLE 1 Electrolyte concentrations measured before (T0) and 5 (T5), 60 (T60), and 120 minutes (T120) after IV administration of 7.2% HTS or
20% MAN to dogs with suspected intracranial hypertension
Osmotherapeutic solution and sample size
Variable Time point N HTS N MAN P value
Sodium (mEq/L [mmol/L])
(RI: 143-151 mEq/L)
T0 15 148.0 ± 5.15 13 149.3 ± 5.38 .52
T5 15 157.8 ± 5.28* 13 141.0 ± 6.16* <.001
T60 13 154.6 ± 5.65*,** 9 147.3 ± 6.55** .01
T120 12 152.9 ± 4.78*,** 7 148.0 ± 3.99** .03
Chloride (mEq/L [mmol/L])
(RI: 109-117 mEq/L)
T0 15 112.5 ± 5.01 13 113.2 ± 5.54 .75
T5 15 125.8 ± 6.33* 13 109.1 ± 6.30* <.001
T60 13 121.6 ± 5.17*,** 10 111.9 ± 6.17** <.001
T120 12 120.7 ± 5.38*,** 8 111.6 ± 4.30** <.001
Chloridecorrected (mEq/L [mmol/L]) T0 15 111.8 ± 4.11 13 111.4 ± 3.46 .79
T5 15 117.2 ± 4.01* 13 113.7 ± 3.94* .03
T60 13 115.7 ± 3.48* 9 112.1 ± 3.52 .02
T120 12 116.0 ± 3.69* 7 111.4 ± 3.51** .01
Potassium (mEq/L [mmol/L])
(RI: 3.6-4.8 mEq/L)
T0 15 3.92 ± 0.43 13 3.98 ± 0.36 .70
T5 15 3.56 ± 0.37* 13 4.07 ± 0.44 .002
T60 13 4.01 ± 0.48** 10 4.03 ± 0.51 .89
T120 12 3.91 ± 0.38 8 3.81 ± 0.45 .58
Ionized Calcium (mg/dL [mmol/L])
(RI: 4.92-5.60 mg/dL [1.23-1.40 mmol/L])
T0 15 4.96 (4.72-5.12) (1.24 [1.18-1.28]) 13 5.0 (4.96-5.36) (1.25 [1.24-1.34]) .09
T5 15 4.68 ± 0.2 (1.17 ± 0.05) 13 4.88 ± 0.36 (1.22 ± 0.09)* .07
T60 13 4.88 ± 0.36 (1.22 ± 0.09) 10 5.2 ± 0.32 (1.30 ± 0.08)** .03
T120 12 4.48 ± 0.28 (1.21 ± 0.07) 8 5.12 ± 0.28 (1.28 ± 0.07)** .03
Note: Data are presented as mean ± SD for normally distributed data or median (interquartile range) for nonnormally distributed data.
Abbreviations: HTS, hypertonic saline; MAN, mannitol; N, sample size; RI, institutional reference interval.33
Note: P-values refer to differences between HTS and MAN treatment at a given time point. *Different with respect to T0 within a treatment group (adjusted
P < .05). **Different with respect to T5 within a treatment group (adjusted P < .05). ***Different with respect to T60 within a treatment group (adjusted P < .05).
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different between HTS and MAN groups (7.5 ± 7.4 and 6.7 ± 5.3 mL/
kg; P = .74). Further details on dose and type of additionally adminis-
tered IV crystalloid fluids can be found in Supplemental Table 1. Dogs
in the HTS group received a median of 3.7 mL/kg/h (range, 0-17 mL/
kg/h) and dogs in the MAN group received a median of 5 mL/kg/h
(range, 0-10 mL/kg/h) of additional isotonic crystalloid fluids (P = .71).
TABLE 2 Acid-base variables measured before (T0) and 5 (T5), 60 (T60), and 120 minutes (T120) after IV administration of 7.2% HTS or 20%
MAN to dogs with suspected intracranial hypertension
Osmotherapeutic solution and sample size
Variable Time point N HTS N MAN P value
pH (RI: 7.35-7.45) T0 15 7.36 ± 0.07 13 7.33 ± 0.10 .31
T5 15 7.35 ± 0.06 13 7.35 ± 0.07 .90
T60 13 7.37 (7.34-7.43) 10 7.37 (7.30-7.39) .43
T120 12 7.39 (7.32-7.43) 8 7.37 (7.30-7.41) .50
PvCO2 (mm Hg) (RI: 28.6-44.7 mm Hg) T0 15 39.59 ± 8.98 13 43.35 ± 13.39 .38
T5 15 38.54 ± 9.57 13 38.55 ± 6.95 .99
T60 13 35.88 ± 6.20 10 40.74 ± 6.07 .07
T120 12 36.25 (28.98-40.85) 8 40.70 (36.35-50.48) .13
Bicarbonate (act) (mEq/L [mmol/L]) (RI: 18.1-26.3 mEq/L) T0 15 21.93 ± 4.13 13 21.75 ± 3.12 .89
T5 15 20.52 ± 3.85* 13 20.75 ± 3.07 .86
T60 13 20.42 ± 3.13 10 21.86 ± 3.20 .29
T120 12 20.50 ± 3.23 8 23.31 ± 2.36** .04
Bicarbonate (std) (mEq/L [mmol/L]) (RI: 19.7-24.8 mEq/L) T0 15 21.87 ± 2.88 13 21.11 ± 2.39 .45
T5 15 20.72 ± 2.69* 13 20.82 ± 2.65 .92
T60 13 21.30 (14.9-23.4) 10 22.2 (14.8-25.0) .81
T120 12 21.05 ± 2.39 8 21.95 ± 1.88 .38
BE (ecf) (mEq/L [mmol/L]) (RI: −6.7 to 1.5 mEq/L) T0 15 −3.44 ± 4.36 13 −4.16 ± 3.22 .62
T5 15 −5.10 ± 3.98* 13 −4.83 ± 3.65 .85
T60 13 −4.80 (−5.95-[−1.95]) 10 −2.8 (−4.8-[−1.5]) .45
T120 12 −4.71 ± 3.43 8 −2.56 ± 1.90** .12
BE (B) (mEq/L [mmol/L]) (RI: −5.3 to 1.3 mEq/L) T0 15 −3.00 ± 3.72 13 −4.16 ± 3.22 .38
T5 15 −4.55 ± 3.43* 13 −4.42 ± 3.31 .91
T60 13 −3.70 (−13.0-[−1.1]) 10 −2.40 (−12.2-0.50) .65
T120 12 −4.03 ± 3.17 8 −2.70 ± 2.17 .31
AG (mEq/L [mmol/L]) (RI: 11.6-21.2 mEq/L) T0 15 17.43 ± 5.23 13 18.35 ± 4.14 .61
T5 15 15.04 ± 4.52* 13 15.23 ± 4.76* .91
T60 13 16.58 ± 4.89 9 17.21 ± 3.26 .73
T120 12 15.64 ± 4.58 7 16.80 ± 4.50 .59
Albumin (g/dL) (RI: 3.0-4.1 g/dL) T0 14 3.90 ± 0.45 11 3.56 ± 0.64 .12
AGcorr (mEq/L [mmol/L]) T0 14 17.43 ± 4.15 11 20.21 ± 4.01 .10
SID (mEq/L [mmol/L]) (RI: 34-40 mEq/L) T0 15 40.56 ± 4.85 13 41.37 ± 3.70 .62
T5 15 36.75 ± 4.60* 13 37.21 ± 3.93* .77
T60 13 38.21 ± 4.36* 9 40.27 ± 3.61** .25
T120 12 37.35 ± 4.16* 7 40.90 ± 3.85** .08
Note: Data are presented as mean ± SD for normally distributed data or median (interquartile range) for nonnormally distributed data.
Abbreviations: AG, anion gap; AGcorr, anion gap corrected for albumin concentration; BE (ecf, extracellular base excess; BE (B), blood base excess;
Bicarbonate (act), actual bicarbonate concentration; Bicarbonate (std), standard bicarbonate concentration; HTS, hypertonic saline; MAN, mannitol; N,
sample size; PvCO2, venous partial pressure of carbon dioxide; RI, institutional reference interval
33 except for SID, which was derived from35; SID, strong
ion difference.
Note: P-values refer to differences between HTS and MAN treatment at a given time point. *Different with respect to T0 within a treatment group
(adjusted P < .05). **Different with respect to T5 within a treatment group (adjusted P < .05). ***Different with respect to T60 within a treatment group
(adjusted P < .05).
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3.3 | Plasma electrolyte concentrations
Plasma electrolyte concentrations in the 2 treatment groups
at the 4 sampling time points are summarized in Table 1. No
significant differences in plasma electrolyte concentrations
were found at T0 between the HTS and MAN group. Plasma
sodium and chloride concentrations were significantly higher in
the HTS group than in the MAN group at T5, T60, and T120.
Plasma potassium concentrations were significantly higher in
the MAN group at T5, as were ionized plasma calcium concentra-
tions at T60 and T120.
Plasma sodium and chloride concentrations were significantly
increased from T0 at T5, T60, and T120 after administration of HTS.
At T60 and T120, plasma sodium and chloride concentrations had
returned to being significantly lower than at T5. After MAN admin-
istration, plasma sodium and chloride concentrations were signifi-
cantly decreased from T0 at T5, but this difference was not
maintained at T60 and T120. Plasma potassium concentrations
after HTS administration were transiently significantly lower at T5
compared with T0. After MAN administration, plasma ionized
calcium concentrations were transiently significantly lower at T5
compared with T0.
3.4 | Acid-base variables
Acid-base variables for both treatment groups at the 4 sampling time
points are summarized in Table 2. Actual bicarbonate concentration at
T120 was significantly higher in the MAN group. No statistically signifi-
cant differences were found in any other acid-base variables between
the 2 treatment groups at any time points.
The pH and PvCO2 did not differ significantly over time within
treatment groups. In the HTS group, actual bicarbonate concentra-
tion, extracellular BE, and AG were significantly lower at T5 than at
T0, whereas in the MAN group actual bicarbonate and extracellular
BE were significantly higher at T120 than at T5 and AG was lower at
T5 than at T0. Strong ion difference in the HTS group was signifi-
cantly lower than at T0 at all subsequent time points. In the MAN
group, SID at T5 was significantly lower than at T0 and at T60 and
T120 was significantly higher than at T5.
3.5 | Plasma albumin concentration
Full plasma biochemical results including albumin concentrations
were available for 25 dogs at T0 and are included in Table 2. No
repeat plasma albumin concentrations were available at any study
time points. Seven measured plasma albumin concentrations fell
outside of the institutional RI for dogs. In the HTS group, they
included hypoalbuminemia of 2.97 g/dL in 1 dog and hyper-
albuminemia ranging from 4.45 to 4.61 g/dL in 3 dogs. In the MAN
group, they included hypoalbuminemia ranging from 2.30 to 2.95 g/
dL in 3 dogs.
4 | DISCUSSION
In our study, the duration and magnitude of electrolyte and acid-base
effects of IV administered 7.2% HTS and 20% MAN to a cohort of
dogs with suspected ICH were evaluated. Plasma electrolyte concen-
trations differed significantly between the 2 treatment groups for at
least 1 of the assessed time points. In dogs receiving HTS, plasma
sodium and chloride concentrations were significantly higher than in
dogs receiving MAN throughout the study period. Plasma sodium and
chloride concentrations in the HTS group increased significantly by T5
compared to baseline, and these increases were maintained at all time
points. In contrast, after MAN administration, they decreased signifi-
cantly by T5 compared to baseline, and these changes were not
maintained at T60 and T120. A transient decrease in plasma potassium
concentration was seen in the HTS group at T5, followed by mild
increases above baseline at T60 in the HTS and MAN groups. The
plasma ionized calcium concentration transiently decreased at T5 in
the MAN group, followed by increases above baseline at T60 and T120.
No changes in pH or respiratory acid-base variables were observed
between groups or over time within either treatment group. Actual
bicarbonate concentration in the MAN group was higher than in HTS
at T120 and, in the HTS group, actual bicarbonate concentration, extra-
cellular BE, and AG were significantly lower at T5 than at baseline.
The changes in acid-base variables were minor and considered
unlikely to be of clinical relevance in dogs with normal acid-base bal-
ance before administration of hyperosmolar agents.
4.1 | Plasma electrolyte concentrations
In addition to osmotherapy, HTS solutions can be used in patients
with symptomatic hyponatremia to accomplish controlled increases in
serum sodium concentration.4,9,36,37 As such, a significant and parallel
increase in plasma sodium and chloride concentrations after the
administration of HTS but not MAN in the current study was
expected. The prescribed dose of 4 mL/kg of 7.2% HTS equates to
4.9 mEq/kg of sodium, which, based on sodium deficit calculations,
should increase a patient's plasma sodium concentration by approxi-
mately 7 mEq/L and the magnitude of the mean plasma sodium con-
centration increase observed in our study was consistent with these
calculations.36 As previously published, the maximum plasma osmolar-
ity in this cohort of dogs occurred at T5 after both HTS and MAN
administration.29 It therefore appears most likely that the decrease in
plasma sodium and chloride concentrations in the MAN group at the
same time point is secondary to the significant osmolarity increase.
With the addition of MAN to the intravascular space, water moves
from the intracellular and interstitial spaces to the intravascular space,
thereby decreasing plasma electrolyte concentrations by dilution.19
The return of plasma sodium and chloride concentrations to values
similar to baseline could be explained by 2 factors: either a rapid
decrease in osmolarity and dilutional effect, or the onset of MAN
induced diuresis. Because osmolarity at T60 and T120 in this group of
dogs remained significantly increased from baseline, it seems more
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likely that urinary losses and intravascular fluid volume contractions
contributed to normalization of plasma sodium and chloride concen-
trations.18,29 Hypertonic saline and MAN both increase plasma osmo-
larity29 and cause significant changes in plasma sodium and chloride
concentrations over time that are more pronounced after HTS admin-
istration. Hypertonic saline therefore should be used cautiously in
patients with unknown baseline plasma electrolyte concentrations,
especially in patients in which dysnatremia or dyschloremia could be
present. Alternatively, in patients with confirmed underlying electro-
lyte abnormalities, MAN could be considered. Because of MAN's
potential to alter intravascular fluid volume and (to a lesser extent
than HTS) plasma electrolyte concentrations, close monitoring of car-
diovascular status and serial measurements of plasma electrolyte con-
centrations still should be performed. Mannitol furthermore should
only be administered to euvolemic and euhydrated patients to mini-
mize the risk of hypovolemia and more pronounced electrolyte
changes.
In the HTS group, plasma potassium concentration showed a signif-
icant transient decrease below baseline at T5, which most likely was
caused by a dilutional effect at the time of peak osmolarity.29 After T5,
the plasma potassium concentrations in both treatment groups followed
a pattern of increase by T60 and then decrease to slightly below base-
line by T120. In people, transient hyperkalemia is described after intra-
vascular volume expansion with both HTS and MAN.20,22,38 The most
commonly cited mechanism for hyperkalemia development is cellular
dehydration leading to increased intracellular potassium concentrations
with a subsequent increase in passive potassium outflow from the intra-
cellular space down its concentration gradient, and it is likely that it was
also the primary mechanism at play in the dogs in our study.22,38 In con-
trast to our study, people receiving MAN during intracranial tumor re-
section show prolonged increases in serum potassium concentrations
up to 180 minutes postinfusion. However, the administered MAN
doses were higher at 1.5 g/kg IV,38 and our shorter follow-up time and
patients lost because of euthanasia limit the comparison. Patients with
renal impairment also have been shown to experience transient, clini-
cally relevant hyperkalemia after infusion of 5% HTS, with peak plasma
potassium concentrations occurring at 150 to 180 minutes.20 In our
patient population of dogs suffering from ICH, changes in plasma potas-
sium concentration were milder, more transient, and unlikely to be clini-
cally relevant. Enrolled patients did not show evidence of renal failure,
but the risk of prolonged or more pronounced hyperkalemia should be
kept in mind if administering hypertonic agents to patients with concur-
rent renal dysfunction or at higher doses, and plasma potassium con-
centrations should be monitored closely in patients at risk for
developing hyperkalemia.
In the HTS group, plasma ionized calcium concentration did not
differ significantly from baseline at any sampling time point, but
decreased below RI after HTS administration. In the MAN group,
plasma ionized calcium concentration decreased significantly but tran-
siently by T5 and then increased to concentrations higher than base-
line, but this difference was not significant. Alkalemia is a well-
established cause of ionized hypocalcemia, and experimental meta-
bolic and respiratory alkalosis decrease the concentration of and
response to parathyroid hormone, thus enabling hypocalcemia.39,40
Based on normal mean pH and actual bicarbonate concentrations at
T5, alkalemia or metabolic alkalosis do not appear to be responsible
for the transient hypocalcemia, and a dilutional effect at the time of
peak osmolarity seems more likely.29 The increase in plasma ionized
calcium concentration and the significant difference in the HTS group
at T60 and T120 after MAN administration could be secondary to
decreased calciuresis during extracellular volume depletion. Extracel-
lular volume contraction may impair renal clearance of ionized cal-
cium.41,42 Mannitol has been shown to induce a significant and
sustained diuresis after IV administration and it remains possible that
extracellular volume contraction contributes to the increases in
plasma ionized calcium concentration.18 However, the beginning
decrease in plasma ionized calcium concentration by T120, when MAN
diuresis and volume contraction should still be ongoing, makes it less
likely that it is the main mechanism at play. More likely, the fading of
a dilutional effect that was present 5 minutes after MAN administra-
tion could explain the apparent increase in plasma ionized calcium
concentration.
Blood for measurement of electrolyte and acid-base variables in
our study was collected into nonbalanced lithium heparin (LH) tubes
instead of blood gas syringes containing dry calcium-balanced LH typi-
cally recommended for the measurement of ionized calcium concen-
trations. Nonbalanced LH can complex and decrease the amount of
measurable ionized calcium, leading to significant concentration dif-
ferences measured from LH tubes and blood gas syringes in
dogs.33,43,44 The blood sampling method used in our study therefore
could have contributed to low measured plasma ionized calcium con-
centrations. However, given that the same sampling method was
employed at every sampling time point, changes of plasma ionized cal-
cium concentration over time should still be evaluable. Overall, at the
doses described herein, changes in plasma ionized calcium concentra-
tion were small in both groups and unlikely to be clinically relevant if
patients have normal plasma ionized calcium concentration at the time
of treatment.
4.2 | Acid-base variables
Neither HTS nor MAN was found to cause clinically relevant alter-
ations in acid-base balance in this cohort of dogs with suspected ICH.
No abnormalities in PvCO2 as the marker of the respiratory system
were observed between groups or within groups over time. Venous
blood samples were used for acid-base analysis in our study and the
site of blood sample collection might have influenced acid-base vari-
ables. Statistically significant differences in pH, PCO2, and bicarbonate
concentrations exist when comparing arterial with venous blood sam-
ples in healthy research dogs.45 These differences are relatively small
and in critically ill people with adequate peripheral perfusion, venous
blood samples are considered an adequate substitute for arterial
blood samples for the purpose of acid-base analysis.46,47 Although
arterial PCO2 would have been ideal to assess the respiratory system,
PvCO2 is considered an acceptable replacement in this cohort of
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cardiovascularly stable dogs, and the added anesthesia time required
for placement of, and increased potential morbidity risk associated
with, arterial catheter placement could not be justified.
In our study, the recorded pH remained within institutional RI in
both groups at most time points, indicating that the few statistically
significant differences in metabolic variables were also unlikely to be
clinically relevant.
The actual bicarbonate concentration in the HTS group decreased
significantly by T5 and remained decreased throughout the study
period. In the MAN group, the actual bicarbonate concentration at
T120 was significantly higher than at T5 and at that time point was sig-
nificantly higher than in the HTS group. Metabolic acidosis is a known
consequence of the administration of both isotonic saline and HTS
solutions.26,48 The most abundant strong ions that are completely or
nearly completely dissociated in plasma are sodium and chloride and
their difference (the SID) makes blood plasma alkaline.25 When equal
amounts of sodium and chloride ions, such as in HTS, are added to
plasma with a lower baseline chloride than sodium concentration, SID
decreases and the blood plasma becomes more acidic.24,25 Hypertonic
saline induced hyperchloremia was documented in our patient popula-
tion and is therefore the most likely explanation for this observed rel-
ative metabolic acidosis compared to baseline. Despite statistically
significant changes over time, actual bicarbonate concentrations
remained within institutional RI at all time points and changes are con-
sidered unlikely to be of clinical importance. The dogs in the HTS
group however had a low normal mean plasma chloride concentration
and minimally increased mean SID before administration of HTS. This
likely contributed to their ability to tolerate the administered chloride
load without a potentially clinically relevant decrease in bicarbonate
concentration and pH below RI. These findings therefore cannot be
extrapolated to patients with preexisting hyperchloremia or metabolic
acidosis. Additional studies are needed to investigate the extent of
HTS-induced metabolic acidosis in such patient populations and, until
more information is available, HTS should only be used cautiously in
ICH patients with concurrent hyperchloremia or metabolic acidosis.
In contrast, patients treated with MAN in our study experienced
a statistically significant increase of actual bicarbonate concentration
by T120, and different pathophysiological processes could have con-
tributed to the development of this relative metabolic alkalosis. The
administration of 2 g/kg of MAN to dogs with concurrent ICH and
hypotension induces significant and prolonged diuresis, starting at
90 minutes after administration, and is maintained beyond
210 minutes.18 Although the aforementioned study showed no
impairment of macroperfusion parameters despite pronounced diure-
sis, metabolic alkalosis secondary to a decrease in effective circulating
volume also has been described.27,28 In our study, neither urine out-
put nor cardiovascular parameters were recorded at the blood sam-
pling intervals, and an assessment of effective circulating volume
status at the time of bicarbonate increase was not possible. Based on
previous studies, it is unlikely for substantial diuresis and hypovolemia
to be present 1 hour after MAN administration, but they could have
developed and contributed to the increase in bicarbonate concentra-
tion by T120. Alternatively, osmotic diuretics previously have been
shown to induce increased renal bicarbonate production.49 Given the
relatively rapid increase in bicarbonate concentration in this group of
dogs, however, this seems to be a less likely explanation than a
decrease in effective circulating volume. Mean actual bicarbonate
concentrations before MAN administration was in the lower half of
the institutional RI in this cohort of dogs. The exacerbation or devel-
opment of clinically relevant metabolic alkalosis after MAN adminis-
tration remains possible and, especially in patients with preexisting
metabolic alkalosis or suspicion for hypovolemia, MAN should be used
with caution.
No differences in extracellular BE and AG were seen between
treatment groups at any time point. The significant differences from
baseline and T5 at T5 and T120 respectively can be explained by
changes in the bicarbonate concentration at the same time points.
Four dogs in the current study were hypoalbuminemic before study
drug administration, which can lead to decreases in AG and mask the
presence of unmeasured anions.34,35 Anion gap at baseline, where
plasma albumin concentration was known, therefore was corrected
and was not significantly different between treatment groups.
Although changes in plasma albumin concentration over time were
not monitored in our study, the changes in uncorrected AG after HTS
and MAN administration suggest a lack of accumulation of
unmeasured anions.
The changes in SID over time in the MAN group can be explained
by the previously discussed shifts in total body water distribution and
associated changes in plasma sodium and chloride concentrations. As
water shifts from the intracellular to the intravascular space, the
excess in free water and dilutional decrease in plasma sodium concen-
tration lead to a decrease in SID that is only maintained until MAN-
induced diuresis sets in. In the HTS group, decreases in SID compared
with baseline can be explained by an imbalance of strong ions because
of a more pronounced increase in plasma chloride concentration com-
pared with sodium concentration.24,50
4.3 | Limitations
Despite its prospective nature, our study had several limitations. First,
a small number of dogs receiving a single dose of a hyperosmolar
agent were enrolled in the study. This number was decreased further
by technical difficulties or euthanasia that precluded the measure-
ments of every electrolyte and acid-base variable at every sample time
point for all initially enrolled patients. Although the exclusion of dogs
requiring additional doses of hyperosmolar treatment might have
introduced a selection bias toward less severely affected dogs, the
fact that some of the dogs initially entered into the study were eutha-
nized speaks against it.
Second, nonbalanced LH tubes were used for electrolyte and
acid-base sample collection via vacutainer system. This system was
chosen to allow for the most consistent sampling method for evalua-
tion of coagulation parameters in our accompanying study.29 For most
consistent and reliable measurements of acid-base variables, samples
ideally should be anaerobically collected into purpose-made blood gas
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syringes and analyzed immediately.51 In comparison with anaerobic
blood samples, samples collected into LH tubes show a significantly
lower PvCO2, a decrease in bicarbonate concentration, and an
increase in pH.51 Similar findings have been reported when comparing
the 2 sampling methods using the RAPIDpoint 500 system in dogs.33
Panels derived from LH tubes showed significant differences in pH,
PvCO2, actual bicarbonate, extracellular BE, ionized calcium, and
AG.33 Blood BE, standardized bicarbonate, and the remaining electro-
lyte concentrations were not significantly different.33 Because of
these reports, standard bicarbonate and blood BE were included in
our data analysis and found to show very similar changes between
and within groups as actual bicarbonate and extracellular BE.
Third, full plasma biochemistry results were inconsistently avail-
able at baseline and were not repeated at subsequent sampling time
points. Albumin is an anion that contributes substantially to the nor-
mal AG. If hypoalbuminemia is present, the AG is decreased and may
fail to identify the presence of unmeasured anions.34,35 Strong ion gap
(SIG) would have been an alternative measure to evaluate for the
presence of unmeasured anions that is not influenced by plasma albu-
min concentrations. The calculation of SIG most commonly includes
phosphorus, which was not measured in our study, and therefore SIG
could not be evaluated.52 The decision to only assess RAPIDpoint
500 panels after study drug administration was made to minimize
patient blood loss, and because of our concurrent study, blood sam-
ples for complete coagulation and hematological analyses were priori-
tized.29 A substantial accumulation of unmeasured anions that would
have justified the reevaluation of biochemical panels furthermore was
not expected secondary to HTS or MAN administration.
Most dogs in our study received isotonic crystalloid fluid therapy
in addition to the hypertonic treatment assigned. Treatment with iso-
tonic crystalloid fluids was at the discretion of the primary clinician if
deemed indicated for additional patient stabilization, and could not be
withheld for the purpose of our study for ethical reasons. The variable
amount of isotonic crystalloid fluids administered in our study is a
confounding variable and it is possible that this intervention blunted
or contributed to changes in the variables evaluated. However, the
administered amounts were similar in both the HTS and MAN groups.
Lastly, our study evaluated changes in plasma electrolyte concen-
trations and acid-base variables in dogs with suspected ICH that, in
the majority of patients, was secondary to intracranial neoplasia or
TBI. No comorbidities leading to clinically relevant metabolic derange-
ments were evident in the study population, and therefore the results
cannot be extrapolated to dogs with concurrent preexisting metabolic
abnormalities. The lack of blinding and the exclusion of dogs that
required additional doses of hyperosmolar therapy from the study
constitute sources of bias. It is likely that more pronounced changes
in electrolyte and acid-base variables can be observed in patients with
more severe ICH requiring multiple doses of hyperosmolar agents and
further prospective studies are necessary to investigate the extent
and importance of such changes.
In conclusion, dogs suffering from ICH treated with HTS or
MAN showed significant changes in plasma electrolyte concentra-
tions. Hypertonic saline administration led to an increase in plasma
sodium and chloride concentrations sustained until 2 hours after
administration, whereas transient decreases 5 minutes after MAN
administration were observed. Changes in acid-base variables were
mild and unlikely to be clinically relevant in this cohort of dogs with
normal baseline acid-base status. Care should be taken when using
hyperosmolar agents in dogs with preexisting electrolyte or acid-
base abnormalities and volume status and electrolyte and acid-base
variables should be monitored carefully.
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